The neuropeptide Orexin is involved in the regulation of the sleep-awake cycle and feeding behavior. We isolated a 22-kb genomic clone containing the 5 0 flanking region of the mouse Orexin promoter. We determined that the transcription start site (+1) is located 96 nucleotides upstream of the initiation codon. The start site region contained consensus sequences corresponding to the transcription initiator and TATA box. Analysis of promoter activity using PC12 cells showed that regions between À13 and +112 and between À1;868 and À780 contained nerve growth factor (NGF)-responsive positive regulatory element and a negative regulatory element respectively.
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The neuropeptide Orexin plays important roles in the regulation of the sleep-awake cycle and feeding behaviors. 1, 2) A recent report showed that fasting leads to increased expression of orexin mRNA in the lateral hypothalamus of the rat, 3) suggesting that feeding regulates the expression of the orexin gene. Hence, to understand the regulation of the sleep-awake cycle and feeding behavior at the molecular level, it is of interest to investigate the mechanisms controlling the expression of the orexin gene, including the regulation of its promoter activity. Although the mouse preproorexin gene has been cloned, 4) the structure and function of the mouse orexin (mOrexin) promoter has not been investigated. In this study, we isolated and characterized the mOrexin promoter.
We screened 10 6 recombinant clones from a mouse BALB/c genomic library (Clontech, Mountain View, CA) with a cDNA probe encoding mouse preproorexin mRNA, which was obtained by RT-PCR. The cDNA product was labeled with [
32 P]dCTP (Amersham, Piscataway, NJ) using random primers (random primer DNA labeling kit; Takara, Ohtsu, Japan). The membranes were hybridized at 42 C in a buffer containing 5 Â SSPE (1 Â SSPE ¼ 0:15 M NaCl, 10 mM NaH 2 PO 4 , 1 mM EDTA, pH 7.0), 50% formamide, 0.2 mg/ml of denatured salmon sperm DNA (ss DNA)/ml, 5 Â Denhardt's solution, 0.1% SDS, and the labeled cDNA probe (1 Â 10 6 cpm/ml), and then washed at 55 C in 1 Â SSPE and 0.1% SDS. We isolated a 22-kb genomic clone that we mapped by restriction enzyme digestion and southern blot hybridization using the cDNA probe. A 3.8-kb SacI fragment containing 3.6-kb of the 5 0 flanking region upstream of the initiation codon was subcloned into the pBluescript (Stratagene, La Jolla, CA) vector and sequenced (Fig. 1A) .
Next we identified the position of the transcription initiation site of the mOrexin promoter using Cap Site cDNA mouse brain (Nippon Gene, Tokyo, Japan). 5, 6) Following the manufacturer's instructions, two consecutive PCRs were performed using two nested sets of primers. For pair 1, the forward primer was 1RC (5 0 -CAAGGTACGCCACAGCGTATG-3 0 ) and the reverse primer was Orexin1 (5 0 -GGATGTGGCTCTAGCTCT-GC-3 0 ). For pair 2, the forward primer was 2RC (5 0 -GTACGCCACAGCGTATGATGC-3 0 ) and the reverse primer was Orexin2 (5 0 -ATGGTCAGGATGCCAGCT-GC-3 0 ). The cycling conditions were 94 C/1 min followed by 35 cycles of 94 C/30 s, 58 C/30 s, 72 C/ 30 s, and 72 C/10 min. The final PCR products were cloned into pGEM-T easy vector (Promega, Madison, WI) and sequenced. The transcription initiation site (+1) was localized 96 nucleotides upstream of the initiation codon. The sequence around this start site was similar to the consensus transcription initiator sequence (Py Py A þ1 N T/A Py Py) (Fig. 1A) . 7) A canonical TATA box sequence (TATAAA) was observed À29 to À24 nucleotides upstream of this initiation site (Fig. 1A) . These structural features of the mOrexin promoter strongly suggest that the mOrexin promoter is TATA box-dependent. In addition, sequence analysis indicated that the mOrexin promoter contains an SP1 binding site * These authors contributed equally to this work. y To whom correspondence should be addressed. Tel: +81-3-5477-2318; Fax: +81-3-5477-2317; E-mail: kida@nodai.ac.jp Abbreviations: NGF, nerve growth factor; cDNA, complementary DNA; dCTP, 2 0 -deoxycytidine 5 0 -triphosphate; mRNA, messenger RNA; RT-PCR, reverse transcriptase-polymerase chain reaction; MEF2, myocyte enhancer factor 2; SDS, sodium dodecyl sulfate; EDTA, ethylene diamine tetra acetate at positions À152 to À157, a GC box at À835 to À845, and an MEF2 binding site at À869 to À878. The 0.1-kb 5 0 -flanking region of the mOrexin promoter showed extensive homology with the human orexin promoter (Fig. 1B) . We also observed 19 polymorphisms in the mOrexin promoter from nucleotides À700 to +94 between BALB/c and C57BL/6 mice (GeneBankÔ accession No., NT 165773). Importantly, the transcription start site of the mOrexin promoter was located downstream of the position corresponding to the start site of the human promoter (Fig. 1B) . 4, 8) To assay the activity of the mOrexin promoter, we constructed a series of plasmids containing different lengths of the 5 0 flanking region of the mOrexin promoter fused to the promoterless luciferase gene, as described previously. 9) We subcloned a fragment corresponding to nucleotides À1868 to +112 into the Cisreporter vector (Stratagene) using PCR and generated deletion mutants of the mOrexin promoter using Exonuclease III (Fig. 2) . PC12 and Cos-1 cells were cultured as described previously. 10, 11) Cells grown in 12-well plates were transiently transfected with plasmids containing either deletion mutants of the mOrexin promoter (500 ng) or the period 1 promoter (500 ng) 10) and pCMX-expressing -galactosidase (50 ng) using Carlsbad, CA) according to the manufacturer's instructions. Forty-eight h after transfection, we measured the activities of luciferase and -galactosidase, as previously described. 10) In PC12 cells, the mOrexin promoter activity was increased by treatment for 24 h with Nerve Growth Factor (NGF, 10 ng/ml), which induces differentiation of PC12 cells to neuron-like cells and is known to be involved in the regulation of hypothalamus function ( Fig. 2A) . [12] [13] [14] [15] Sequential deletions of the region corresponding to nucleotide positions À1868 to À118 appeared to have little effect on the promoter activity in the presence and the absence of NGF-treatment ( Fig. 2A) . In contrast, the deletion construct to À13 failed to respond to NGF. Importantly, we observed no activation of period 1 promoter in response to NGF-treatment (Fig. 2B) . These results suggest that the region between À118 and À13 contains a positively responsive element to NGF-treatment in PC12 cells. In addition, sequential deletions of the promoter region from nucleotides À1868 to À780 increased the promoter activity without affecting its response to NGF-treatment. Therefore, the region between nucleotides À1868 and À780 perhaps contains a negative regulatory element in PC12 cells. Because the expression of orexin is restricted to the Orexin neurons of the hypothalamus, suppression of the activity of this negative regulatory region might restrict activation of the mOrexin promoter to orexin neurons. Furthermore, we observed lower activity of the mOrexin promoter in COS-1 cells than in PC12 cells (Fig. 2C) . Additionally, NGF-treatment did not affect the promoter activities of the mOrexin (À682 mutant) or the period 1 in COS-1 cells (Fig. 2D) . Taken together, these observations suggest that the Orexin promoter shows tissue-specific activity.
Previous reports have shown that the Orexin regulatory element (OE) 1 is required for hypothalamusspecific expression of the human orexin gene. However, the deletion of sequence (À292 to À80), corresponding to human OE1, did not affect the promoter activity in the presence or the absence of NGF-treatment in PC12 cells Twenty-four h after transfection, PC12 and COS-1 cells were treated with or without NGF (10 ng/ml) for 24 h. pCMX-was co-transfected as a control for transfection efficiency. Luciferase activity was normalized to the -galactosidase activity. All reporter assays were performed in triplicate in three independent experiments. Each value represents the mean plus or minus SD.
( Fig. 2A) , suggesting that the OE1 is functional in orexin neurons in the hypothalamus. Further investigation of the function of the mOrexin promoter should allow us to understand the regulation of the expression of the Orexin gene in vivo.
